How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?

被引：1
|
作者：
Takigawa, Nagio [1 ]
机构：
[1] Kawasaki Med Sch, Dept Gen Internal Med 4, Kita Ku, 2-6-1 Nakasange, Okayama 7008505, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
OPEN-LABEL; ACQUIRED-RESISTANCE; CRIZOTINIB; CHEMOTHERAPY; IDENTIFICATION; INHIBITION; MUTATIONS; CERITINIB;
D O I：
10.1016/j.jtho.2018.07.009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1438 / 1440
页数：3
相关论文
共 50 条
  • [31] Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Siying
    Wang, Ruoyao
    Han, Wei
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] An overview of alectinib hydrochloride as a treatment option for ALK positive non-small cell lung cancer
    Schokrpur, Shiruyeh
    Hilburn, Van
    Giustini, Nicholas
    Bazhenova, Lyudmila
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (14) : 1815 - 1824
  • [33] The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer
    Amanam, Idoroenyi
    Gupta, Rohan
    Mambetsariev, Isa
    Salgia, Ravi
    FUTURE ONCOLOGY, 2018, 14 (19) : 1897 - 1908
  • [34] Role of STK11 in ALK-positive non-small cell lung cancer
    Zhou, Wen
    Yan, Lu-Da
    Yu, Zhi-Qiong
    Li, Na
    Yang, Yong-Hua
    Wang, Meng
    Chen, Yuan-Yuan
    Mao, Meng-Xia
    Peng, Xiao-Chun
    Cai, Jun
    ONCOLOGY LETTERS, 2022, 23 (06)
  • [35] Personalized Medicine Tackles Clinical Resistance: Alectinib in ALK-Positive Non-Small Cell Lung Cancer Progressing on First-Generation ALK Inhibitor
    Skoulidis, Ferdinandos
    Papadimitrakopoulou, Vassiliki A.
    CLINICAL CANCER RESEARCH, 2016, 22 (21) : 5177 - 5182
  • [36] Alectinib in the treatment of ALK-positive metastatic non-small cell lung cancer: clinical trial evidence and experience with a focus on brain metastases
    Tomasini, Pascale
    Egea, Julie
    Souquet-Bressand, Maxime
    Greillier, Laurent
    Barlesi, Fabrice
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [37] Enteral administration of alectinib for ALK-positive non-small cell lung cancer in an elderly patient A case report
    Thomas, Quentin Dominique
    Pautas, Marie
    Guilhaume, Marie-Noelle
    Fiteni, Frederic
    Ge, Tony
    Girard, Nicolas
    MEDICINE, 2021, 100 (43) : E27611
  • [38] Alectinib in the treatment of ALK-positive non-small cell lung cancer: an update on its properties, efficacy, safety and place in therapy
    Vavala, Tiziana
    Novello, Silvia
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
  • [39] Indirect comparisons of brigatinib and alectinib for front-line ALK-positive non-small-cell lung cancer
    Reckamp, Karen L.
    Lin, Huamao M.
    Cranmer, Holly
    Wu, Yanyu
    Zhang, Pingkuan
    Walton, Laura J.
    Kay, Stephen
    Cichewicz, Allie
    Neupane, Binod
    Fahrbach, Kyle
    Popat, Sanjay
    Camidge, D. Ross
    FUTURE ONCOLOGY, 2022, 18 (20) : 2499 - 2510
  • [40] A Bayesian network meta-analysis of ALK inhibitor treatments in patients with ALK-positive non-small cell lung cancer
    Zheng, Bei
    Jiang, Hong
    Yang, Wenjuan
    Li, Ying
    Liang, Bingqing
    Zhu, Jun
    Chen, Nanmei
    Chen, Miao
    Zhang, Meiling
    CANCER MEDICINE, 2023, 12 (15): : 15983 - 15997
12345